Publications

Search our bibliography using the filters on the right-hand side.

Displaying 101 through 150 of 237 publications.

Patterson BJ, Myers K, Stewart A, Mange B, Hillson EM, Poulos C. Preferences for herpes zoster vaccination among adults aged 50 years and older in the United States: results from a discrete choice experiment. Expert Rev Vaccines. 2021 Jul 22. doi: 10.1080/14760584.2021.1910502

Wilson MR, McDade CL, Perdrizet JE, Mignon A, Farkouh RA, Wasserman DM. Validation of a novel forecasting method for estimating the impact of switching pneumococcal conjugate programs: evidence from Belgium. Infect Dis Ther. 2021 Jul 12. doi: 10.1007/s40121-021-00485-9

Ghaswalla P, Davis K, Sweeney C, Davenport E, Trofa A, Herrera-Restrepo O, Buck P. Knowledge, attitudes, practices and barriers regarding Hepatitis A and Hepatitis B vaccination: a survey of healthcare providers. Poster presented at the American Association of Nurse Practitioners (AANP) National Conference; June 15, 2021.

La EM, Garbinsky D, Hunter S, Poston S, Novy P, Ghaswalla P. Meningococcal B vaccination coverage among older adolescents in the United States. Vaccine. 2021 May 6;39(19):2660-7. doi: 10.1016/j.vaccine.2021.03.071

La E, Poston S, Curran D, Lorenc S, Salem AE, Carrico J, Hicks KA, Anderson S, Carpenter CF. Cost-effectiveness analysis of recombinant zoster vaccine for vaccinating immunocompromised adults against Herpes Zoster in the United States. Presented at the ACIP Herpes Zoster Working Group; April 2021. Atlanta, GA.

Njue A, Coyne C, Margulis AV, Wang D, Marks MA, Russell K, Das R, Sinha A. The role of congenital cytomegalovirus infection in adverse birth outcomes: a review of the potential mechanisms. Viruses. 2020 Dec 24;13(1):E20. doi: 10.3390/v13010020

Carrico J, La EM, Talbird SE, Chen YT, Nyaku MK, Carias C, Marshall GS, Roberts CS. Economic impact of routine childhood immunization in the 2017 United States birth cohort. Presented at the Virtual ISPOR Europe 2020 Conference; November 2020. [abstract] Value Health. 2020 Dec 1; 23(Supplement 2):S427. doi: 10.1016/j.jval.2020.08.039

Hunter S, Garbinsky D, La EM, Poston S, Hogea C. Impact of state of residence on adult vaccination uptake: a multilevel modeling approach. Presented at the IDWeek 2020 Virtual Conference; October 21, 2020.

La EM, Carrico J, Talbird SE, Chen YT, Nyaku MK, Carias C, Marshall GS, Roberts CS. Current estimates of the impact of routine childhood immunizations in reducing vaccine-preventable diseases in the United States. Poster presented at the IDWeek 2020 Virtual Conference; October 21, 2020.

Ghaswalla PK, Garbinsky D, Poston S, Hunter S, Novy P, La EM. Correlates of and disparities in meningococcal B vaccination coverage among 17-year-olds in the United States: a pooled analysis of 2016-2018 National Immunization Survey-Teen. Poster presented at the 2020 Virtual American Academy of Pediatrics National Conference; October 2, 2020.

La EM, Garbinsky D, Hunter S, Poston S, Novy P, Ghaswalla P. Individual and state-level factors associated with receipt of multiple recommended adolescent vaccines in the United States. Presented at the IDWeek 2020 Virtual Conference; October 2020.

Talbird SE, La EM, Carrico J, Poston S, Poirrier JE, DeMartino JK, Hogea CS. Impact of population aging on the burden of vaccine-preventable diseases among older adults in the United States. Hum Vaccin Immunother. 2020 Aug 6;1-12. doi: 10.1080/21645515.2020.1780847

Wilson MR, Wasserman MD, Breton MC, Peloquin F, Earnshaw SR, McDade C, Sings HL, Farkouh RA. Health and economic impact of routine pediatric pneumococcal immunization programs in Canada: a retrospective analysis. Infect Dis Ther. 2020 Aug;9(2):341-53. doi: 10.1007/s40121-020-00294-6

Aris E, Montourcy M, Esterberg E, Kurosky SK, Poston S, Hogea C. The adult vaccination landscape in the United States during the Affordable Care Act era: results from a large retrospective database analysis. Vaccine. 2020 Mar;38(14):2984-94. doi: 10.1016/j.vaccine.2020.02.057

Sacco P, Myers K, Poulos C, Sweeney C, Hollis K, Snow V, Vietri JT. Preferences for adult pneumococcal vaccine recommendations among United States health care providers. Infect Dis Ther. 2019 Dec;8(4):657-70. doi: 10.1007/s40121-019-00266-5

Standaert B, Van Vlaenderen I, Van Bellinghen LA, Talbird SE, Hicks K, Carrico J, Buck PO. Constrained optimization for the selection of influenza vaccines to maximize the population benefit: a demonstration project. Appl Health Econ Health Policy. 2019 Nov 22. doi: 10.1007/s40258-019-00534-y

Wilson M, Moffatt M, Mignon A, McDade C, Wasserman M. Potential public health impact model assessing the switch back to use of the 13-valent infant pneumococcal conjugate vaccine in Belgium on children under 18 years. Poster presented at the World Society for Pediatric Infectious Diseases (WSPID) Conference; November 2019. Manila, Philippines.

Njue A, Margulis AV, Lyall M, Nuabor W, Marks M, Russell K, Sinha A. Congenital cytomegalovirus: what are the rates of maternal screening, diagnostic amniocentesis, and elective termination? Poster presented at the ID Week 2019; October 4, 2019. Washington, DC.

Kurosky SK, Esterberg E, Irwin DE, Trantham L, Packnett E, Novy P, Whelan J, Hogea C. Meningococcal vaccination among adolescents in the United States: a tale of two age platforms. J Adolesc Health. 2019 Jul;65(1):107-15. doi: 10.1016/j.jadohealth.2019.02.014

Herring W, Rosen B. Economic model for ResVax for maternal vaccination against infant respiratory syncytial virus disease in the United States. Presented at the 2019 Respiratory Syncytial Virus Consortium in Europe; June 2019. Utrecht, The Netherlands.

Talbird SE, La EM, Carrico J, Poston S, Poirrier JE, DeMartino JK, Hogea C. Cost-benefit analysis of vaccination against four preventable diseases in older adults in the United States. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 21, 2019. New Orleans, LA.

Esterberg E, Kurosky SK, Trantham L, Irwin D, Packnett E, Novy P, Whelan J, Hogea C. Impact of healthcare utilization on meningococcal adolescent vaccination in the United States (US). Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 21, 2019. New Orleans, LA.

Aris E, Montourcy M, Esterberg E, Kurosky SK, Poston S, Hogea C. Vaccination and potential missed opportunities among adults in the United States during the Affordable Care Act era. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 20, 2019. New Orleans, LA.

Gould I, Herring W, Benninghoff B, Standaert B. Explaining the rotavirus serotype-distribution shift in children after vaccination using a simple transmission model. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 21, 2019. New Orleans, LA. [abstract] Value Health. 2019 May; 22(Supplment 2):S202-3.

Crawford R, Doward L, Conroy R, Saretsky T, Sinha A. Living with congenital cytomegalovirus: a conceptual model of impact for patients and caregivers. Poster presented at the 2019 Pediatric Academic Societies (PAS) Meeting; April 28, 2019. Baltimore, MD.

Butler AM, Layton JB, Krueger WS, Kshirsager AV, McGrath LJ. Assessing residual bias in estimating influenza vaccine effectiveness: comparison of high-dose versus standard-dose vaccines. Med Care. 2019 Jan;57(1):73-8. doi: 10.1097/MLR.0000000000001018

Curran D, Patterson BJ, Van-Oorschot D, Buck PO, Carrico J, Hicks KA, Lee B, Yawn BP. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live. Hum Vaccin Immunother. 2019;15(4):765-71. doi: 10.1080/21645515.2018.1558689.

Wasserman M, Palacios MG, Grajales AG, Berenice Baez-Revueltas F, Wilson M, McDade C, Farkouh R. Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico. Hum Vaccin Immunother. 2019;15(3):560-9. doi: 10.1080/21645515.2018.1516491

Wilson M, Wasserman M, Breton MC, Peloquin F, McDade C, Earnshaw S, Farkouh R. Estimating the clinical and economic impact of switching from the 13-valent to 10-valent pneumococcal conjugate vaccine in Quebec. Poster presented at the Canadian Immunization Conference (CIC) 2018; December 5, 2018. Ottawa, Canada.

Wasserman M, Wilson M, Earnshaw S, McDade C, Pugh S, Moffatt M, Sings H, Hilton B, Farkouh R. Predicting invasive pneumococcal disease incidence: a forecasting approach. Poster presented at the Canadian Immunization Conference (CIC) 2018; December 5, 2018. Previously presented at the 11th International Symposium on Pneumococci and Pneumococcal Diseases.

Breton MC, Peloquin F, Wasserman M, Wilson M, McDade C, Farkouh R. Pneumococcal vaccination provides substantial value for money for Canadians. Poster presented at the Canadian Immunization Conference (CIC) 2018; December 5, 2018. Ottawa, Canada. Previously presented at the IDWeek 2017 Conference.

Talbird SE, La EM, Mauskopf J, Altland A, Daniels V, Wolfson LJ. Understanding the role of exogenous boosting in modeling varicella vaccination. Expert Rev Vaccines. 2018 Nov;17(11):1021-35. doi: 10.1080/14760584.2018.1538801

Breton MC, Farkouh R, Vojicic J, Wilson M, McDade C, Wasserman M. Modeling reductions in antibiotic prescriptions due to otitis media in Canada as a result of pneumococcal vonjugate vaccination. Poster presented at the IDWeek 2018 Conference; October 5, 2018. San Francisco, CA.

Talbird SE, La EM, Carrico J, Poston S, Poirrier J, DeMartino JK, Hogea C. Projected burden of vaccine-preventable diseases in older adults in the United States: impact of population aging. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain. [abstract] Value Health. 2018 Oct; 21(Supplement 3):S225.

McGrath LJ, Layton JB, Krueger WS, Kshirsagar AV, Butler AM. High-dose influenza vaccine use among patients receiving hemodialysis in the United States, 2010-2013. Vaccine. 2018 Oct 1;36(41):6087-94. doi: 10.1016/j.vaccine.2018.08.079

Layton JB, Butler AM, Panozzo CA, Brookhart MA. Rotavirus vaccination and short-term risk of adverse events in US infants. Paediatr Perinat Epidemiol. 2018 Sep;32(5):448-57. doi: 10.1111/ppe.12496

Curran D, Patterson B, Varghese L, van Oorschot D, Buck P, Carrico J, Hicks K, Lee B, Yawn B. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States. Vaccine. 2018 Aug 9;36(33):5037-45. doi: 10.1016/j.vaccine.2018.07.005

Butler AM, Layton JB, Krueger WS, Kshirsagar AV, McGrath LJ. Estimating influenza vaccine effectiveness: using an active comparator reduces bias due to confounding by frailty. Poster presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 25, 2018. Prague, Czech Republic. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug; 27(S2):229. doi: 10.1002/pds.4629

Wilson M, Wasserman M, Earnshaw S, McDade C, Pugh S, Moffatt M, Sings H, Hilton B, Farkouh R. Predicting invasive pneumococcal disease incidence: a forecasting approach. Poster presented at the 11th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); April 16, 2018. Melbourne, Australia.

Wasserman M, Lucas A, Wilson M, Farkouh R, Brogan A, Hilton B, Jones D. Dynamic transmission modeling to address infant pneumococcal conjugate vaccine schedule modifications. Poster presented at the 11th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); April 16, 2018. Melbourne, Australia.

Patterson B, Curran D, Buck P, Varghese L, Oorschot D, Carrico J, Hicks K, Lee B, Yawn B. Cost-effectiveness of candidate adjuvanted subunit vaccine for vaccinating U.S. adults not previously vaccinated against herpes zoster. Poster presented at the 2018 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 25, 2018. Boston, MA. [abstract] J Manag Care Pharm. 2018 Apr; 24(4-a):S20.

Buck PO, Curran D, Patterson BJ, Varghese L, van Oorschot D, Carrico J, Hicks K, Lee BY, Yawn BP. Cost-effectiveness of adjuvanted recombinant zoster vaccine (RZV) for vaccinating US adults not previously vaccinated against herpes zoster. Poster presented at the 2018 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 25, 2018. [abstract] J Manag Care Pharm. 2018 Apr; 24(4-a):S20.

Patterson B, Buck P, Pawlowski J, Carrico J, Hicks K, Curran D, van Oorschot D, Lee B, Yawn B. Herpes zoster (HZ) revaccination strategies: assessment of the potential HZ and postherpetic neuralgia case avoidance in the United States for people previously vaccinated against HZ. Poster presented at the American Pharmacists Association (APhA) Annual Meeting; March 17, 2018. Nashville, TN. Previously presented at the American Society Health System Pharmacist (ASHP) Conference.

Patterson B, Buck P, Pawlowski J, Carrico J, Hicks K, Curran D, van Oorschot D, Lee B, Yawn B. Assessment of the potential herpes zoster and postherpetic neuralgia case avoidance with vaccination in the United States. Poster presented at the American Pharmacists Association (APhA) Annual Meeting; March 17, 2018. Nashville, TN. Previously presented at the IDWeek 2017 Conference.

La EM, Trantham L, Kurosky SK, Odom D, Aris E, Hogea C. An analysis of factors associated with influenza, pneumoccocal, Tdap, and herpes zoster vaccine uptake in the US adult population and corresponding inter-state variability. Hum Vaccin Immunother. 2018 Feb 1;14(2):430-41. doi: 10.1080/21645515.2017.1403697

Patterson BJ, Buck PO, Carrico J, Hicks K, Curran D, van Oorschot D, Pawlowski JE, Lee BY, Yawn BP. Herpes zoster (HZ) revaccination strategies: assessment of the potential HZ and post herpetic neuralgia case avoidance in the US for people previously vaccinated against HZ. Poster presented at the American Society Health System Pharmacist (ASHP) Midyear Clinical Meeting and Exhibition; December 5, 2017. Orlando, FL.

Graham J, Talbird SE, Monsanto H, Perez Bolde-Villareal C, Daniels V, Pillsbury M, Wolfson LJ. Budget impact of a one-dose varicella vaccination program using outputs of a dynamic transmission model: Mexican national perspective. Poster presented at the 17th Annual Congress of the Sociedad Latinoamericana de Infectología Pediátrica (SLIPE); November 2017. Cancun, Mexico.

Patterson BJ, Buck PO, Carrico J, Hicks KA, Curran D, van Oorschot D, Pawlowski JE, Lee BY, Yawn BP. Assessment of the potential herpes zoster and post herpetic neuralgia case avoidance with vaccination in the United States. Poster presented at the IDWeek 2017 Conference; October 6, 2017. San Diego, CA.

Baker M, Jankosky C, Yih K, Gruber S, Li L, Cocoros N, Lipowicz H, Coronel-Moreno C, Feibelmann S, Lin N, McMahill-Walraven C, Menschik D, Selvan M, Selvam N, Tilney RC, Zichittella L, Lee G, Kawai AT. The risk of febrile seizures following influenza and 13-valent pneumococcal conjugate vaccines. Poster presented at the 2017 Infectious Disease Week Conference; October 6, 2017. San Diego, CA. [abstract] Open Forum Infect Dis. 2017 Oct; 4(Suppl 1):S464-5. doi: 10.1093/ofid/ofx163.1187

Patterson B, Curran D, Buck P, Varghese L, Oorschot D, Carrico J, Hicks K, Lee B, Yawn B. Cost-effectiveness of candidate adjuvanted subunit vaccine for revaccinating U.S. adults previously vaccinated against herpes zoster. Poster presented at the 2017 AMCP NEXUS; October 18, 2017. Dallas, TX. [abstract] J Manag Care Spec Pharm. 2017 Oct; 23(10-a):S20.